Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Endogenous Metabolite
    (3)
  • Others
    (13)
Filter
Search Result
Results for "

α-galactosidase

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    18
    TargetMol | Inhibitors_Agonists
  • Natural Products
    5
    TargetMol | Natural_Products
  • Recombinant Protein
    4
    TargetMol | Recombinant_Protein
  • Antibody Products
    6
    TargetMol | Antibody_Products
  • Cell Research
    4
    TargetMol | Inhibitors_Agonists
α-Galactosidase
Alpha-Galactosidase
T761349025-35-8
α-Galactosidase is an endogenous glycosidase that can break down oligosaccharides and glycolipids containing α-galactoside bonds and can be used in the study of Fabry disease.
  • $36
7-10 days
Size
QTY
β-Galactosidase
GAL
T736159031-11-2
β-Galactosidase (GAL) is a glycoside hydrolase that hydrolyzes the β-glycosidic bond formed between galactose and its organic part, and naturally catalyzes the hydrolysis of the galactosidic bond in oligosaccharides and disaccharides for the degradation of lactose and the production of low-lactose and lactose-free lactose products that are beneficial to lactose intolerant patients.
  • $87
In Stock
Size
QTY
Lyso-Globotriaosylceramide (d18:1)
Lyso-Globotriaosylceramide (d18:1)
T37291126550-86-5
Lyso-globotriaosylceramide is a form of globotriaosylceramide that is lacking the fatty acyl group. It binds to Shiga toxin 1 (Stx1) in the presence of cholesterol and phosphatidylcholine but does not bind Stx2. It also reduces viability and aggregation of human neutrophils induced by phorbol 12-myristate 13-acetate when used at concentrations of 50 and 1 μM, respectively. Lyso-globotriaosylceramide accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. It also accumulates in the urine, kidney, and plasma of patients with Fabry disease. Lyso-globotriaosylceramide levels decrease in response to administration of the α-galactosidase inhibitor 1-deoxygalactonojirimycin in a transgenic mouse model of Fabry disease. Decreases in plasma and urine concentrations of lyso-globotriaosylceramide have been used as a biomarker for efficacy of enzyme replacement therapy (ERT) and other therapies in the treatment of Fabry disease.
  • TBD
35 days
Size
QTY
Stachyose hydrate
T580954261-98-2
Stachyose hydrate is a natual product,it highly promotes proliferation of lactic acid bacteria (LAB) by inducing LAB to produce more α-galactosidase to hydrolyze stachyose.
  • $33
In Stock
Size
QTY
Raffinose
Melitose, Melitriose
T8144512-69-6
Raffinose (Melitriose) is an indigestible short-chain oligosaccharide, a trisaccharide composed of galactose, glucose and fructose, found in many plants. It can be hydrolyzed by α-galactosidase (α-GAL) to D-galactose and sucrose.
  • $42
In Stock
Size
QTY